4.7 Article

Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection

期刊

ANNALS OF SURGICAL ONCOLOGY
卷 25, 期 2, 页码 558-564

出版社

SPRINGER
DOI: 10.1245/s10434-017-6253-0

关键词

-

资金

  1. KKF TU Munich
  2. Biogen Idec
  3. Quintiles
  4. MSD Sharp Dome
  5. Boehringer Ingelheim
  6. Inventive Health Clinical UK Ltd.
  7. Advance Cor
  8. Brainsgate
  9. Pfizer
  10. Bayer-Schering
  11. Novartis
  12. Roche
  13. Servier
  14. Penumbra
  15. WCT GmbH
  16. Syngis
  17. SSS International Clinical Research
  18. PPD Germany GmbH
  19. Worldwide Clinical Trials Ltd.
  20. Phenox
  21. Covidien
  22. Actelion
  23. Medivation
  24. Medtronic
  25. Harrison Clinical Research
  26. Concentric
  27. Pharmtrace
  28. Reverse Medical Corp.
  29. Premier Research Germany Ltd.
  30. Surpass Medical Ltd.
  31. GlaxoSmithKline
  32. ERC grant

向作者/读者索取更多资源

Incomplete resection of glioblastoma is discussed controversially in the era of combined radiochemotherapy. The aim of this study was to analyze the benefit of subtotal tumor resection for glioblastoma patients as this was recently questioned in the era of radiochemotherapy. Overall, 209 patients undergoing surgery for newly diagnosed WHO grade IV gliomas were retrospectively analyzed, and pre- and postoperative tumor volumes were manually segmented (cm(3)). Survival analyses were performed, including prognostic factors such as age, Karnofsky performance score (KPS), O-6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, and adjuvant treatment regimen. Pre- and postoperative tumor volume is significantly associated with pre- and postoperative KPS, as well as age (p < 0.001). Postoperative tumor volume remained a significant prognostic factor in a multivariate analysis, independent of other prognostic factors (hazard ratio 1.0365, 95% confidence interval 1.0235-1.0497, p < 0.001). In the era of molecularly-driven radiochemotherapy, glioblastoma surgery remains a major prognostic factor. Even in situations in which a gross total resection cannot be achieved, maximum safe reduction of tumor burden should be attempted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据